Results 31 to 40 of about 18,162 (243)

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Microbiology Spectrum, 2022
To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon, according to prior exposure to raltegravir (RAL).
Joseph Fokam, Ezechiel Ngoufack Jagni Semengue, Evariste Molimbou, Naomi-Karell Etame, Maria Mercedes Santoro, Désiré Takou, Leonella Mossiang, Alain Patrice Meledie, Collins Ambe Chenwi, Bouba Yagai, Alex Durand Nka, Beatrice Dambaya, Georges Teto, Aude Christelle Ka’e, Grâce Angong Beloumou, Sandrine Claire Djupsa Ndjeyep, Nadine Fainguem, Aissatou Abba, Aurelie Minelle Ngueko Kengni, Michel Carlos Tommo Tchouaket, Nounouce Pamen Bouba, Serge-Clotaire Billong, Rina Djubgang, Edith Temgoua Saounde, Samuel Martin Sosso, Charles Kouanfack, Anne-Cecile Zoung-Kanyi Bissek, Emmanuel Eben-Moussi, Vittorio Colizzi, Carlo-Federico Perno, Francesca Ceccherini-Silberstein, Alexis Ndjolo   +31 more
doaj   +1 more source

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +5 more sources

Features of application of raltegravir in HIV-infected patients with different somatic pathologies

Журнал инфектологии, 2021
Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova, E. S. Obizhaeva, S. O. Mayorova   +2 more
doaj   +1 more source

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients [PDF]

, 2011
Objectives To compare the frequency of previously in vitro-selected integrase mutations (T124A, T124A/S153F, S153Y, T124A/S153Y and L101I/T124A/S153Y) conferring resistance to S/GSK1349572 between HIV-1 subtype B integrase inhibitor (INI)-naive and ...
Armenia, D, Calvez, V, Ceccherini-Silberstein, F, Fabeni, L, Fourati, S, Katlama, C, Malet, I, Marcelin, A, Masquelier, B, Perno, CF, Sayon, S, Wirden, M   +11 more
core   +1 more source

Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique

Iraqi Journal of Pharmaceutical Sciences, 2018
The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone  s630 was utilized.
Ahmed S. Abdul Jabbar
doaj   +1 more source

Adverse events of raltegravir and dolutegravir. [PDF]

, 2017
To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Prospective cohort study.
Battegay, Manuel, Bernasconi, Enos, Calmy, Alexandra, Cavassini, Matthias, Elzi, Luigia, Erb, Stefan, Furrer, Hansjakob, Günthard, Huldrych, Swiss HIV Cohort Study, Vernazza, Pietro   +9 more
core   +4 more sources

Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes. [PDF]

, 2017
BackgroundThe Literature on rhabdomyolysis in the HIV-positive population is sparse and limited. We aimed to explore the incidence, patient characteristics, etiologies and outcomes of rhabdomyolysis in a cohort of HIV-positive patients identified through
Atta, Mohamed G, Estrella, Michelle M, Fine, Derek M, Koubar, Sahar H, Lucas, Gregory M, Moore, Richard D, Warrier, Rugmini   +6 more
core   +1 more source

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.

PLoS ONE, 2019
Antiretroviral agents are approved in Japan based on non-clinical and clinical data reported from overseas. Neither the long-term tolerability nor the effectiveness of raltegravir or other integrase strand transfer inhibitors in Japan is known.
Naho Kuroishi, Asuka Watananbe, Ryuta Sakuma, Daniel J Ruzicka, Mitsuyoshi Hara   +4 more
doaj   +1 more source

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence

Frontiers in Microbiology, 2019
The human immunodeficiency virus type 1 (HIV-1) has several proteins of therapeutic importance, many of which are currently used as drug targets in antiretroviral therapy. Among these proteins is the integrase, which is responsible for the integration of
Lucas de Almeida Machado, Marcelo Ferreira da Costa Gomes, Ana Carolina Ramos Guimarães   +2 more
doaj   +1 more source

Towards a Patent Pool for HIV Medicines: The Background [PDF]

, 2010
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time,
Childs, Michelle
core   +2 more sources